Antitumorigenic effect of combination treatment with BRAF inhibitor and cisplatin in colorectal cancer in vitro and in vivo
Authors:
Preprint
- 21 March 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose In colorectal cancer (CRC), BRAF inhibitor (BRAFi) monotherapy appears ineffective, while cisplatin treatment is associated with adverse effects, drug resistance and reduced efficacy. Herein, we seek to explore a combinatorial approach to increase the likelihood of effectively killing colorectal cancer cells. Methods We examined the combined effect of BRAFi (PLX4720, Vemurafenib, Dabrafenib, Encorafenib) and cisplatin treatment in BRAFV600E-mutated (RKO, HT29, Colo-205) and BRAFwt (Caco-2) cell lines, as well as in mouse xenografts of RKO cells. Results Following cisplatin-only treatment, all cell lines showed accumulation within subG1 (apoptotic cells) and G2/M phases, as well as phosphorylation of ERK1/2 and H2AX. Following BRAFi-only treatment, BRAFV600E-mutated cells showed accumulation within G0/G1 phase, reduced distribution in the S and G2/M phases, inhibition of ERK1/2 phosphorylation and increased phosphorylation of H2AX. BRAFi had no effect on BRAFwt Caco-2 cell line. Combined BRAFi and cisplatin treatment synergistically decreased RKO cells viability, reduced phosphorylation of ERK1/2 and increased phosphorylation of H2AX. Importantly, in mouse xenografts of RKO cells, combined PLX4720 and cisplatin treatment showed superior therapeutic potential than each monotherapy (P < 0.001). Conclusion In in vitro and in vivo preclinical models, BRAFi and cisplatin combined treatment has shown an improved antitumor effect, rendering it a potential anticancer treatment strategy for BRAF-mutant colon cancer patients.Keywords
All Related Versions
This publication has 56 references indexed in Scilit:
- Design and Synthesis of Novel 2‐Acetamido, 6‐Carboxamide Substituted Benzothiazoles as Potential BRAFV600E Inhibitors – In vitro Evaluation of their Antiproliferative ActivityChemMedChem, 2023
- SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)Clinical and Translational Oncology, 2018
- Clinical Pharmacokinetics and Pharmacodynamics of DabrafenibClinical Pharmacokinetics, 2018
- Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cellsCancer Letters, 2016
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Continuous ERK Activation Downregulates Antiproliferative Genes throughout G1 Phase to Allow Cell-Cycle ProgressionCurrent Biology, 2006
- UV Irradiation Triggers Ubiquitin-Dependent Degradation of p21WAF1 to Promote DNA RepairCell, 2003
- Integrating the MAP kinase signal into the G1 phase cell cycle machineryBioEssays, 2000
- CIS‐diamminedichloroplatinum(II) inhibits p34cdc2 protein kinase in human lung‐cancer cellsInternational Journal of Cancer, 1993
- Cis-Pt(NH3)2Cl2 and trans-Pt(NH3)2Cl2 inhibit DNA synthesis in cultured L1210 leukemia cellsBiochemical and Biophysical Research Communications, 1983